Jubilant Life Sciences gains 5% on USFDA approval for hypertension drug

Epic Update Jubilant Life SciencesEpic Update Jubilant Life Sciences

Share price of Jubilant Life Sciences added 5.7 percent intraday Tuesday on USFDA approval for Olmesartan Medoxomil tablets.

The company has received Abbreviated New Drug Application (ANDA) final approval for Olmesartan Medoxomil tablets, 5mg, 20 mg and 40 mg, the generic version of Benicar of Daiichi Sankyo, which is used for treatment of hypertension.

This is second approval that company has received from the USFDA during the current financial year.

As on December 2016, the company had a total of 73 ANDAs for oral solids filed in the US, out of which 49 have been approved.

Jubilant Life Sciences was quoting at Rs 829.70, up Rs 39.50, or 5 percent on the BSE.

For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co

Facebook Twitter YouTube Pinterest Linkedin Google+

You may also like:

Sensex, Nifty hold morning gains; Ambuja Cements, ACC rally' width= Nifty hovers around 8800 as investors await RBI policy; ITC up' width=
Sensex, Nifty hold morning gains; Ambuja Cements, ACC rally Nifty hovers around 8800 as investors await RBI policy; ITC up
Share Button

About the Author

Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300